

wherein:

X and Y are N or N(R₃);

Z is C(R₄);

R₁ is selected from a member of the group consisting of hydrogen, substituted methyl, substituted C₍₅₋₉₎alkyl, substituted or unsubstituted C₍₅₋₉₎alkenyl, substituted or unsubstituted C₍₅₋₉₎alkynyl, substituted or unsubstituted C₍₅₋₉₎hydroxyalkyl, substituted or unsubstituted C₍₃₋₈₎alkoxyl, or substituted or unsubstituted C₍₅₋₉₎alkoxyalkyl;

R₂ and R₃ are independently selected from a member of the group consisting of hydrogen, halo, oxo, C₍₁₋₂₀₎alkyl, C₍₁₋₂₀₎hydroxyalkyl, C₍₁₋₂₀₎thioalkyl, C₍₁₋₂₀₎alkylamino, C₍₁₋₂₀₎alkylaminoalkyl, C₍₁₋₂₀₎aminoalkyl, C₍₁₋₂₀₎aminoalkoxyalkenyl, C₍₁₋₂₀₎aminoalkoxyalkynyl, C₍₁₋₂₀₎diaminoalkyl, C₍₁₋₂₀₎triaminoalkyl, C₍₂₋₂₀₎tetraaminoalkyl, C₍₅₋₁₅₎aminotrialkoxyamino, C₍₁₋₂₀₎alkylamido, C₍₁₋₂₀₎alkylamidoalkyl, C₍₁₋₂₀₎amidoalkyl, C₍₁₋₂₀₎acetamidoalkyl, C₍₁₋₂₀₎alkenyl, C₍₁₋₂₀₎alkynyl, C₍₃₋₈₎alkoxyl, C₍₁₋₁₁₎alkoxyalkyl, and C₍₁₋₂₀₎dialkoxyalkyl;

R₄ is selected from a member of the group consisting of hydrogen, halo, oxo, C₍₁₋₂₀₎alkyl, C₍₁₋₂₀₎hydroxyalkyl, C₍₁₋₂₀₎thioalkyl, C₍₁₋₂₀₎alkylamino, dialkylamino, C₍₁₋₂₀₎alkylaminoalkyl, C₍₁₋₂₀₎aminoalkyl, C₍₁₋₂₀₎aminoalkoxyalkenyl, C₍₁₋₂₀₎aminoalkoxyalkynyl, C₍₁₋₂₀₎diaminoalkyl, C₍₁₋₂₀₎triaminoalkyl, C₍₂₋₂₀₎tetraaminoalkyl, C₍₅₋₁₅₎aminotrialkoxyamino, C₍₁₋₂₀₎alkylamido, C₍₁₋₂₀₎alkylamidoalkyl, C₍₁₋₂₀₎amidoalkyl, C₍₁₋₂₀₎acetamidoalkyl, C₍₁₋₂₀₎alkenyl, C₍₁₋₂₀₎alkynyl, C₍₃₋₈₎alkoxyl, C₍₁₋₁₁₎alkoxyalkyl, and C₍₁₋₂₀₎dialkoxyalkyl; and

— — — represents a double or single bond;

with the proviso that R₁ is not an ω-1-hydroxyalkyl group having from 5 to 9 carbon atoms when R₃ is hydrogen or methyl and R₄ is hydrogen.

REMARKS

This supplemental amendment is submitted to amend claim 1. No new matter has been added. Claim 1 is being amended to overcome the disclosure of European Patent No. 0 389 282, which shows a xanthine derivative wherein in R₁ can be an alkyl having 1 to 12 carbon atoms.

Application No.: 09/288,556

See page 5, lines 44-46 of the patent. However, the patent nowhere discloses that the term "alkyl" includes substituted alkyls. Accordingly, claim 1 has been amended so that it does not read on the European patent.

Favorable consideration and prompt allowance of the pending claims are respectfully requested. To the extent necessary, a petition for an extension of time under 37 C.F.R. 1.136 is hereby made. Please charge any shortage in fees due in connection with the filing of this paper, including extension of time fees, to Deposit Account 500417 and please credit any excess fees to such deposit account.

Respectfully submitted,

McDERMOTT, WILL & EMERY



Cameron K. Weiffenbach
Registration No. 44,488

Willem F. Gadiano
Registration No. 37,136


600 13th Street, N.W.
Washington, DC 20005-3096
(202) 756-8000 CKW:ckw
Facsimile: (202) 756-8087
Date: January 31, 2003

APPENDIX

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Please amend claim 1 as follows:

1. (Five Times Amended) A therapeutic compound, including resolved enantiomers, diastereomers, tautomers, salts and solvates thereof, having the following formula (I):



RECEIVED
FEB 06 2003
TECH CENTER 1600/2900

wherein:

X and Y are N or N(R₃);

Z is C(R₄);

R₁ is selected from a member of the group consisting of hydrogen, substituted methyl, substituted C₍₅₋₉₎alkyl, substituted or unsubstituted C₍₅₋₉₎alkenyl, substituted or unsubstituted C₍₅₋₉₎alkynyl, substituted or unsubstituted C₍₅₋₉₎hydroxyalkyl, substituted or unsubstituted C₍₃₋₈₎alkoxyl, or substituted or unsubstituted C₍₅₋₉₎alkoxyalkyl[, the R₁ being optionally substituted];

R₂ and R₃ are independently selected from a member of the group consisting of hydrogen, halo, oxo, C₍₁₋₂₀₎alkyl, C₍₁₋₂₀₎hydroxyalkyl, C₍₁₋₂₀₎thioalkyl, C₍₁₋₂₀₎alkylamino, C₍₁₋₂₀₎alkylaminoalkyl, C₍₁₋₂₀₎aminoalkyl, C₍₁₋₂₀₎aminoalkoxyalkenyl, C₍₁₋₂₀₎aminoalkoxyalkynyl, C₍₁₋₂₀₎diaminoalkyl, C₍₁₋₂₀₎triaminoalkyl, C₍₂₋₂₀₎tetraaminoalkyl, C₍₅₋₁₅₎aminotrialkoxyamino, C₍₁₋₂₀₎alkylamido, C₍₁₋₂₀₎alkylamidoalkyl, C₍₁₋₂₀₎amidoalkyl, C₍₁₋₂₀₎acetamidoalkyl, C₍₁₋₂₀₎alkenyl, C₍₁₋₂₀₎alkynyl, C₍₃₋₈₎alkoxyl, C₍₁₋₁₁₎alkoxyalkyl, and C₍₁₋₂₀₎dialkoxyalkyl;

Application No.: 09/288,556

R_4 is selected from a member of the group consisting of hydrogen, halo, oxo, $C_{(1-20)}$ alkyl, $C_{(1-20)}$ hydroxyalkyl, $C_{(1-20)}$ thioalkyl, $C_{(1-20)}$ alkylamino, dialkylamino, $C_{(1-20)}$ alkylaminoalkyl, $C_{(1-20)}$ aminoalkyl, $C_{(1-20)}$ aminoalkoxyalkenyl, $C_{(1-20)}$ aminoalkoxyalkynyl, $C_{(1-20)}$ diaminoalkyl, $C_{(1-20)}$ triaminoalkyl, $C_{(2-20)}$ tetraaminoalkyl, $C_{(5-15)}$ aminotrialkoxyamino, $C_{(1-20)}$ alkylamido, $C_{(1-20)}$ alkylamidoalkyl, $C_{(1-20)}$ amidoalkyl, $C_{(1-20)}$ acetamidoalkyl, $C_{(1-20)}$ alkenyl, $C_{(1-20)}$ alkynyl, $C_{(3-8)}$ alkoxyl, $C_{(1-11)}$ alkoxyalkyl, and $C_{(1-20)}$ dialkoxyalkyl; and

— - — - represents a double or single bond;

with the proviso that R_1 is not an ω -1-hydroxyalkyl group having from 5 to 9 carbon atoms when R_3 is hydrogen or methyl and R_4 is hydrogen.